ClearGuard HD Caps Recommended for Preventing Bloodstream Infection

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Pursuit Vascular, Inc. announced that the latest edition of NephSAP® featured the company’s ClearGuard HD Antimicrobial Barrier Caps as a key component of a global strategy to reduce bloodstream infections in hemodialysis patients. NephSAP, or Nephrology Self-Assessment Program, is a premiere educational offering for American Society of Nephrology (ASN) members to help them stay abreast of developing areas of nephrology.  The July edition highlights the significant reduction in central-line associated bloodstream infection (CLABSI) rates using ClearGuard HD caps vs. other commonly used caps.

Dr. Daniel Landry, Baystate Medical Center, notes the “dramatic and sustained reduction in CLABSI rates” using ClearGuard HD caps in the two “prospective multicenter randomized controlled trials encompassing more than 533,000 catheter-days” in his accompanying editorial.  He recommends “use of antimicrobial catheter caps for the purpose of preventing CLABSI” as a component of a global strategy to reduce bloodstream infections.

ClearGuard HD caps are also included as a specific prevention strategy for central venous catheters to reduce the risk of bloodstream infection by Eduardo Lacson, Jr., MD at Tufts University School of Medicine, and Alan Kliger, MD, of Yale School of Medicine.  They provide an overview of the two trials using ClearGuard HD caps and conclude “central venous catheter caps with chlorhexidine-coated rods decrease the risk of blood stream infections compared with standard caps or isopropanol-containing caps.”

The July edition of NephSAP is part of the Nephrologists Transforming Dialysis Safety (NTDS) project, an initiative funded by the Centers for Disease Control and Prevention (CDC) aimed at engaging nephrologists to promote infection prevention in dialysis facilities.

“It’s gratifying to see the CDC and ASN recognize ClearGuard HD caps in this special edition of NephSAP,” said Doug Killion, President and CEO of Pursuit Vascular.  “We share a common vision with NTDS in targeting zero infections, and ClearGuard HD caps help make this goal a reality.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.